Skip Navigation Links
Skip Navigation Links

Multiple Myeloma


Randomized phase III trial of bortezomib, lenalidomide, and dexamethasone (VRd) vs carfilzomib, lenalidomide, and dexamethasone (CRd) followed by limited or indefinite duration lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma (ENDURANCE)  ECOG-ACRIN E1A11 (NCT01863550)  (MBMC Contact: Chris Sanders 314-996-5802)

Randomized phase I/II study of optimal induction therapy of bortezomib, dexmethasone, and lenaliomide with or without elotuzumab for newly diagnosed high risk multiple myeloma  SWOG S1211 (NCT 01668719)  (MBMC Contact: Chris Sanders 314-996-5802)  Temporarily closed as of 6/2/16

Phase I/II study of pomalidomide, dexamethasone and ixazomib vs pomalidomide and dexamethose for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor base therapy  A061202 (NCT02004275)  ((MBMC Contact:  Chris Sanders  314-996-5802)  Temporarily closed to accrual as of 6/1/17

Solitary plasmacytoma of bone:  Randomized phase III trial to evaluate treatment with adjuvant systemic treatment and zoledronic acid versus zoledronic acid after definite radiation therapy  Alliance A061402  (NCT 02516423)  (MBMC Contact:  Chris Sanders 314-996-5802)





Melanoma Trials in St. Louis, MO

All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy